We hypothesized that the increased BRD4 copy-number in these samples may be due to large-scale amplifications involving cyclin E1 (CCNE1), a known driver in endometrial, breast, and ovarian cancers, which is also located on chromosome 19. Here, CCNE1 is linked to ovarian carcinoma.